| (Values in U.S. Thousands) | Jul, 2026 | Jul, 2026 | Jul, 2026 | Jul, 2026 | Jul, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Diagnocure (DGCRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Diagnocure Inc. is a life sciences company developing and commercializing highâ€value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 1998, the Company initiated the commercialization of its first diagnostic test, ImmunoCytTM/ uCyt+ TM for bladder cancer in Europe and, in 2000, obtained a 510(k) clearance from the Food and Drug Administration (FDA) for the commercialization of the test in the United States. In August 2008, in order to maximize the value of its portfolio and focus on highâ€value molecular diagnostics, it entered into a product divestment agreement for ImmunoCy/ uCytwith Scimedx Corporation, a U.S.â€based company. In May 2011, DiagnoCure's Previstage GCC Colorectal Cancer Staging Test was featured at the annual meeting of the American Society of Colon and Rectal Surgeons (ASCRS) held in Vancouver, Canada.